Literature DB >> 12468519

18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies.

Tuula Tolvanen1, Kaisa Lehtiö, Jarmo Kulmala, Vesa Oikonen, Olli Eskola, Jörgen Bergman, Heikki Minn.   

Abstract

UNLABELLED: 18F-Fluoroerythronitromidazole (FETNIM) is a new promising PET tracer for imaging tumor hypoxia. Accurate radiation dosimetry is important for estimating absorbed radiation doses to patients and for calculating the allowable injected dose.
METHODS: Radiation absorbed doses were estimated from PET scans obtained on cancer patients on the basis of the MIRD procedure. Dynamic acquisition data was obtained from the thorax, abdomen, and head and neck regions. The tracer was injected intravenously and mean injected activity was 366 MBq (range, 288-385 MBq). Arterial blood was continuously assayed over dynamic PET imaging. The bladder wall dose was evaluated from the voided urine activity measurements.
RESULTS: The effective dose to a 70-kg adult was 0.015 or 0.019 mSv/MBq, calculated on 2- or 4-h voiding intervals, respectively. The critical organ proved to be the urinary bladder wall, with a highest absorbed dose of 0.062 or 0.127 mGy/MBq depending on the voiding schedule as described above. Absorbed doses in all other organs were at least 5-fold smaller than the bladder wall doses.
CONCLUSION: With an injected activity of 370 MBq (18)F-FETNIM, the radiation doses are generally comparable with those of other related radionuclide imaging procedures. Specifically, in comparison with (18)F-fluoromisonidazole, the absorbed doses of (18)F-FETNIM are equal. However, special attention should be given to adequate hydration and voiding to limit the relatively high exposure of the critical organ, bladder wall, to (18)F-FETNIM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468519

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Human radiation dosimetry of [11C]MeAIB, a new tracer for imaging of system A amino acid transport.

Authors:  Tuula Tolvanen; Kjell Någren; Meixiang Yu; Eija Sutinen; Katja Havu-Aurén; Sirkku Jyrkkiö; Markku Asola; Eira Kotoneva; Pirjo Nuutila; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-24       Impact factor: 9.236

2.  Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT.

Authors:  Mohan Doss; James J Zhang; Marie-José Bélanger; James B Stubbs; Eric D Hostetler; Katherine Alpaugh; Hartmuth C Kolb; Jian Q Yu
Journal:  Nucl Med Commun       Date:  2010-12       Impact factor: 1.690

Review 3.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 4.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

Review 5.  Molecular imaging of hypoxia with radiolabelled agents.

Authors:  Gilles Mees; Rudi Dierckx; Christel Vangestel; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-30       Impact factor: 9.236

6.  Suggested pathway to assess radiation safety of ¹⁸F-labeled PET tracers for first-in-human studies.

Authors:  Paolo Zanotti-Fregonara; Adriaan A Lammertsma; Robert B Innis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-19       Impact factor: 9.236

7.  Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism.

Authors:  P Mahy; X Geets; M Lonneux; P Levêque; N Christian; M De Bast; J Gillart; D Labar; J Lee; V Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-04       Impact factor: 9.236

Review 8.  Hypoxia PET Imaging with [18F]-HX4-A Promising Next-Generation Tracer.

Authors:  Sebastian Sanduleanu; Alexander M A van der Wiel; Relinde I Y Lieverse; Damiënne Marcus; Abdalla Ibrahim; Sergey Primakov; Guangyao Wu; Jan Theys; Ala Yaromina; Ludwig J Dubois; Philippe Lambin
Journal:  Cancers (Basel)       Date:  2020-05-22       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.